Aura Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Aura Biosciences, Inc. (AURA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $20.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-11
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $20.00K.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $590.00K, a 47.50% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $600.00K, a 60.00% decline from fiscal 2024.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.50M, a 0.00% change from fiscal 2023.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.50M, a 87.50% increase from fiscal 2022.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $800.00K, a 700.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $20.00K 10-Q · filed 2026-08-11 | $20.00K derived: sum of 3 quarters · filed 2026-08-11 | $610.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-11 | $20.00K derived: sum of 2 quarters · filed 2026-05-11 | $610.00K derived: sum of 3 quarters · filed 2026-05-11 | $620.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $590.00K derived: sum of 2 quarters · filed 2026-03-30 | $600.00K derived: sum of 3 quarters · filed 2026-08-11 | $600.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $590.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $600.00K derived: sum of 2 quarters · filed 2026-08-11 | $600.00K 10-Q · filed 2025-11-13 | $1.30M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $10.00K 10-Q · filed 2026-08-11 | $710.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.11M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $700.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.10M derived: sum of 3 quarters · filed 2026-05-11 | $1.20M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.10M derived: sum of 2 quarters · filed 2026-03-30 | $1.20M derived: sum of 3 quarters · filed 2026-03-30 | $1.50M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $500.00K derived: sum of 2 quarters · filed 2025-11-13 | $800.00K 10-Q · filed 2025-11-13 | $1.30M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $400.00K 10-Q · filed 2025-08-13 | $900.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.00M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-15 | $800.00K derived: sum of 2 quarters · filed 2025-05-15 | $900.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.70M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $600.00K derived: sum of 2 quarters · filed 2025-03-24 | $1.40M derived: sum of 3 quarters · filed 2025-03-24 | $1.50M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $900.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.00M 10-Q · filed 2024-11-12 | $1.00M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $900.00K 10-Q · filed 2024-08-08 | $900.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.10M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-09 | $100.00K derived: sum of 2 quarters · filed 2024-05-09 | $300.00K derived: sum of 3 quarters · filed 2024-05-09 | $800.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $200.00K derived: sum of 2 quarters · filed 2024-03-27 | $700.00K derived: sum of 3 quarters · filed 2024-03-27 | $800.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $700.00K derived: sum of 2 quarters · filed 2023-11-09 | $800.00K 10-Q · filed 2023-11-09 | $890.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $600.00K 10-Q · filed 2023-08-09 | $690.00K derived: sum of 3 quarters · filed 2023-08-09 | $690.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-11 | $100.00 10-Q · filed 2022-05-12 | $190.00K derived: sum of 2 quarters · filed 2023-05-11 | $190.00K derived: sum of 3 quarters · filed 2023-05-11 | $199.99K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $90.00K derived: sum of 2 quarters · filed 2023-03-15 | $99.99K derived: sum of 3 quarters · filed 2023-03-15 | $100.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $9.99K derived: sum of 2 quarters · filed 2022-11-10 | $10.00K 10-Q · filed 2022-11-10 | $10.00K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $9.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $10.00K 10-Q · filed 2022-08-11 | $10.00K derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $10.00 10-Q · filed 2022-05-12 | $10.00 derived: sum of 2 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $20.00K 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $20.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |